Analysts predict that Omnicell Technologies (NASDAQ:OMCL) will report sales of $177.37 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Omnicell Technologies’ earnings, with the lowest sales estimate coming in at $177.32 million and the highest estimate coming in at $177.41 million. Omnicell Technologies posted sales of $150.55 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 17.8%. The company is expected to issue its next quarterly earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Omnicell Technologies will report full-year sales of $177.37 million for the current year, with estimates ranging from $788.21 million to $790.51 million. For the next financial year, analysts forecast that the company will report sales of $879.58 million per share, with estimates ranging from $867.46 million to $898.15 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Omnicell Technologies.
Omnicell Technologies (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.54 EPS for the quarter, beating the Zacks’ consensus estimate of $0.52 by $0.02. The company had revenue of $198.26 million during the quarter, compared to the consensus estimate of $205.50 million. Omnicell Technologies had a return on equity of 1.54% and a net margin of 2.88%. Omnicell Technologies’s revenue was up 13.6% on a year-over-year basis. During the same period last year, the business posted $0.37 earnings per share.
Shares of OMCL traded down $0.05 on Monday, reaching $43.90. 143,286 shares of the company’s stock traded hands, compared to its average volume of 285,202. The company has a current ratio of 1.73, a quick ratio of 1.28 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $1,707.80, a price-to-earnings ratio of 243.89, a PEG ratio of 3.62 and a beta of 0.74. Omnicell Technologies has a 52-week low of $38.00 and a 52-week high of $55.40.
In other Omnicell Technologies news, Director Gary S. Petersmeyer sold 575 shares of the firm’s stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $44.43, for a total value of $25,547.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Randall A. Lipps sold 8,186 shares of the firm’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $44.21, for a total value of $361,903.06. Following the completion of the sale, the chairman now directly owns 224,206 shares of the company’s stock, valued at $9,912,147.26. The disclosure for this sale can be found here. Company insiders own 3.71% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Marco Investment Management LLC purchased a new stake in Omnicell Technologies in the third quarter worth $231,000. Elkfork Partners LLC purchased a new position in shares of Omnicell Technologies in the fourth quarter valued at $225,000. Xact Kapitalforvaltning AB purchased a new position in shares of Omnicell Technologies in the fourth quarter valued at $244,000. Stone Ridge Asset Management LLC purchased a new position in shares of Omnicell Technologies in the fourth quarter valued at $360,000. Finally, USA Financial Portformulas Corp purchased a new position in shares of Omnicell Technologies in the fourth quarter valued at $364,000.
Omnicell Technologies Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Technologies and related companies with MarketBeat.com's FREE daily email newsletter.